Faes Farma (FAE.MC) Akcie Kurz
Faes Farma Kurz
Za posledních 19 let vzrostly tržby Faes Farma o 6,5 % ročně a dosáhly 610,46 Mil. EUR. Zisk na akcii rostl o 2,9 % ročně za posledních 19 let. U Faes Farma je čistá marže 13,0 % dolů oproti 20,7 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 3,72 %. Výplatní poměr je kolem 70 % zisku. Dividenda rostla o 5,5 % ročně za posledních 19 let. Konsenzuální 12měsíční cílová cena pro Faes Farma je 5,61 EUR, asi nad cenu o 16,5 %. Z 10 analytiků jich 6 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Faes Farma
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Faes Farma a analýza akcií
Nejčastější otázky týkající se akcie Faes Farma
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analytici aktuálně stanovují průměrnou cílovou cenu 5,36 EUR pro akcii Faes Farma (medián: 5,61 EUR), tedy +11,0 % vůči poslední ceně. Konsensus vychází z 10 hodnocení analytiků.
10 analytiků aktuálně hodnotí akcii Faes Farma: 6 doporučuje koupit, 3 držet a 1 prodat. Pro rok 2026 analytici očekávají u Faes Farma tržby 758,51 Mil. EUR a zisk na akcii 0,31 EUR.
Akcie Faes Farma (FAE.MC) je kótována na 7 burzách, mimo jiné: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
Tržby očekávané za Faes Farma činí 758,51 Mil. EUR. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Faes Farma činí 96,30 Mil. EUR. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Faes Farma je aktuálně 15,56. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Faes Farma.
Poměr ceny k tržbám (P/S) Faes Farma je aktuálně 1,98. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Faes Farma.
Score kvality pro Faes Farma je 7/10.
ISIN Faes Farma je ES0134950F36. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Faes Farma je A0MKAC. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Faes Farma je FAE.MC. Symbol tickeru se používá k obchodování akcií Faes Farma na burze.
Faes Farma akcie
Faes Farma Peer Group
Faes Farma Ticker
Faes Farma FIGI
Všechny fundamentální údaje o Faes Farma v podrobné analýze
Naše analýzy akcií společnosti Faes Farma zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Faes Farma. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: